GHK-Cu reaches a recovery-focused audience as a repair peptide: copper tripeptide, tissue remodelling, collagen. The literature behind that framing is real, roughly 180 PubMed records. What it studied is the part that gets dropped.
Three registered studies, and what each one is
ClinicalTrials.gov returns three records under the name. None is a trial of an injected preparation.
| Record | What it is |
|---|---|
| NCT05932732 | Completed Phase 4, 27 participants, Austin Institute for Clinical Research. Facial skin quality, hydration and skin barrier across three HydraFacial treatments |
| NCT07706361 | Not yet recruiting, 100 participants, sponsored by LifeWave. Effect of that company's X39 patch on circulating GHK and GHK-Cu |
| Third entry | Filed by a sponsor whose registry records do not survive checking. Not citable |
A cosmetic facial procedure and a wellness patch. Neither answers a question about injecting the compound, and the third record should not be used to fill the gap.
Route is not a detail here
For most peptides the argument against extrapolation is about species: a rodent figure per kilogram does not convert. For this one there is a second and equally serious gap, which is route.
The reputation comes from topical and in vitro work on skin, wound healing and copper transport. A copper complex applied to skin and a copper complex injected are different exposures, and the published record is about the first. Nothing in it establishes what the second does.
What that leaves for a training context
Connective tissue repair claims for this compound rest on cell and animal work plus topical human cosmetic use. There is no registered human trial of an injectable preparation and no approved product anywhere, so a ghk cu dosage figure for injection has no authorised or trial-derived source to restate.
That is not a claim that nothing happens. It is a statement about what has been measured, which is the only thing worth acting on.
The one-minute version
Open the three registry records and read the intervention field on each. A facial treatment, a patch, and one that does not hold up. If that is the trial base, any chart presenting injection quantities is inferring rather than reporting, and it should say so.